Michael Thomas Henderson sold $6.0M of SYRE
director at Spyre Therapeutics, Inc.. 80,000 shares at an average of $74.40, traded May 8, 2026, filed May 8, 2026.
Score components
- +15RoleDirector
- +25Trade size$6.0M at market
- +10Share of holdings soldSold 47% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.9%, 3m +39.8%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001636282-26-000053, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -2,404 | $72.57 | $174k | 166,202 | May 8, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -33,513 | $73.72 | $2.5M | 132,689 | May 8, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -24,814 | $74.76 | $1.9M | 107,875 | May 8, 2026 |
| May 8, 2026 | SOpen-market sale Common Stock10b5-1 | -19,269 | $75.35 | $1.5M | 88,606 | May 8, 2026 |
Related signals
Other insiders at Spyre Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $2.3M 25,000 shares | -26% | |
| 40Moderate | Spyre Therapeutics, Inc. | Heidy King-Jones See Remarks | $2.6M 28,933 shares | -91% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.4M 15,000 shares | -3% | |
| 32Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $2.3M 25,732 shares | -24% | |
| 40Moderate | Spyre Therapeutics, Inc. | Heidy King-Jones See Remarks | $2.5M 28,399 shares | -92% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.3M 15,000 shares | -3% | |
| 40Moderate | Spyre Therapeutics, Inc. | Jeffrey W. Albers director | $2.4M 23,000 shares | -460% | |
| 23Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $717k 7,500 shares | -7% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.4M 15,000 shares | -3% | |
| 22Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $658k 7,500 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.